Volume 31 Number 2 (2022)
Carbimazole-Resistant Graves’ Disease Responding to Oral Prednisolone: A Case Report
Kamrul-Hasan AB1 , Mondal E2
Mymensingh Med J 2022 April; 31 (2): 553-555
PMID: 35383779
Abstract
Conventional management of Graves’ disease includes antithyroid drugs, radioactive iodine and thyroidectomy. Patients rarely may be resistant to antithyroid drugs and may require additional management, including corticosteroids. We treated an 18-year-old girl with Graves’ thyrotoxicosis and resistance to Carbimazole. She was clinically and biochemically hyperthyroid despite getting 75mg Carbimazole and 120mg Propranolol daily. We added tablet Prednisolone (20mg for 15 days, then 10mg for the next 15 days) to Carbimazole (75mg/day). Four weeks later, she was free from thyrotoxic symptoms and her free T4 and total T3 levels normalized. The dose of tablet Prednisolone was lowered to 5mg/day for the next 15 days and Carbimazole was continued at 45mg/day. She received 10mCi Iodine-131 (131I) at this stage and Carbimazole was discontinued. She remained clinically and biochemically euthyroid when she was followed up at 7th and 24th weeks after radioiodine ablation.
Keywords: Graves’ Disease, Carbimazole, Carbimazole-resistance, Prednisolone
- Assistant Professor